Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit

Nesligül Özdemir; Ayçe Çeliker; Bülent Barış Kuşkonmaz; Duygu Uçkan Çetinkaya

Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit

Abstract

Background and Aims: Many drugs with narrow therapeutic range and high toxicity risk are used in hematopoietic stem cell transplantation (HSCT) Units. The increase in the number of drugs raises the likelihood of interactions. This is particularly important in pediatric patients and may adversely affect the treatment process. In this study, we aimed to determine the potential drug interactions and to evaluate the clinical significance of them in terms of physician’s and pharmacist’s perceptions. Methods: The study was conducted as a prospective descriptive study over a six-month period in a tertiary care hospital’s Pediatric HSCT Unit. A pharmacist evaluated inpatients’ drugs for drug interactions by using a drug interaction checker program and the clinical significance of the interactions were evaluated by the physician and the pharmacist separately. Results: Drugs used in 20 patients (median age= 8 years, range= 0.6–17 years) were evaluated. A total of 525 potential drugdrug interactions were identified. Two hundred and forty seven interactions (47.05%) were major; 238 (45.33%) were moderate; 23 (4.38%) were contraindicated. The number of the interactions considered “clinically significant” by the pharmacist and “clinically insignificant” by the physician at the preparative regimen and post-transplant period were 15 (35.7%) and 37 (29.4%), respectively. Conclusion: The management of drug interactions is important in pediatric HSCT patients as a vulnerable group. Drug interactions should be interpreted according to the patient's clinical presentation, not only theoretically. Cooperation between physicians and pharmacists in the management of interactions will contribute to optimize the patient's treatment.

Keywords

References

• Aljadani, R., & Aseeri, M. (2018). Prevalence of drug-drug interactions in geriatric patients at an ambulatory care pharmacy in a tertiary care teaching hospital. BMC Research Notes, 11(1). http:// dx.doi.org 10.1186/s13104-018-3342-5
• Ament, P. W., Bertolino, J.G., & Liszewski, J.L. (2000). Clinically significant drug interactions. American Family Physician, 61(6), 1745–1754.
• Balk, T. E., Van-der-Sijs, I. H., Van-Gelder, T., Janssen, J. J. B., Van-der Sluis IM, Van-Leeuwen, R. W. F., & Engels, F. K. (2017). Drug-drug interactions in pediatric oncology patients. Pediatric Blood Cancer. 64(7). https://doi.org/10.1002/pbc.26410
• Bernard, E., Goutelle, S., Bertrand, Y., & Bleyzac, N. (2014). Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Annals of Pharmacotherapy, 48(12), 1580–1584. https://doi. org/ 10.1177/1060028014550644
• Campana, C., Regazzi, M. B, Buggia, I., & Molinaro, M. (1996). Clinically significant drug interactions with cyclosporin - An update. Clinical Pharmacokinetics, 30(2), 141–179.
• Chan, A., Tan, S. H., Wong, C. M., Yap, K. Y., & Ko, Y. (2009). Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clinical Therapeutics, 31(2), 2379–2386. https://doi. org/10.1016/j.clinthera.2009.11.008
• Deeg, H. J. (2005). Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematology American Society of Hematology Education Program, 167–173.
• Eldesouky, H. E., Li, X., Abutaleb, N. S., Mohammad, H., & Seleem, M. N. (2018). Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris. International Journal of Antimicrobial Agents, 52(6), 754–761. https://doi.org/10.1016/j.ijantimicag.2018.08.016

• Gholaminezhad, S., Hadjibabaie, M., Gholami, K., Javadi, M. R., Radfar, M., Karimzadeh, I., & Ghavamzadeh, A. (2014). Pattern and associated factors of potential drug-drug interactions in both preand early post-hematopoietic stem cell transplantation stages at a referral center in the Middle East. Annals of Hematology, 93(11), 1913–1922.
• Glotzbecker, B., Duncan, C., Alyea, E., Campbell, B., & Soiffer, R. (2012). Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biology of Blood and Marrow Transplantation, 18(7), 989–1006. https://doi. org/ 10.1016/j.bbmt.2011.11.029
• Leather, H. L. (2004). Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplantation, 33(2), 137–152.
• Marcath, L. A., Coe, T. D., Hoylman, E. K., Redman, B. G., & Hertz, D. L. (2018). Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer, 18(1), 1155-1163. http://dx.doi.org/10.1186/ s12885-018-5076-0
• Metzke, B., Hug, M. J., Fink, G., Hieke, S., Jung, M., & Engelhardt, M. (2012). Drug-drug interactions in the hematology and oncology department: a real-life assessment of frequency and severity. Blood, 120(21), 4250–4250. Retrieved from https://www.researchgate. net/publication
• Myers, A. L., Kawedia, J. D., Champlin, R. E., Kramer, M. A., Nieto, Y., Ghose, R., & Andersson, B. S. (2017). Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opinion on Drug Metabolism& Toxicology, 13(9), 901–923. https://doi.org/ 10. 1080/17425255.2017.1360277
• Prot-Labarthe, S., Therrien, R., Demanche, C., Larocque, D., & Bussieres, J. F. (2008). Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service. Journal of Oncology Pharmacy Practice, 14(3), 147–152. https://doi. org/ 10.1177/1078155208093929
• Rodrigues, A. T., Stahlschmidt, R., Granja, S., Pilger, D., Falcao, A. L. E., & Mazzola, P. G. (2017). Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Brazilian Journal of Pharmaceutical Science, 53(1), e16109- e16117. https://doi.org/10.1590/s2175-97902017000116109
• Sadaba, B., Lopez-de-Ocariz, A., Azanza, J. R., Quiroga, J., & Cienfuegos, J. A. (1998). Concurrent clarithromycin and cyclosporin A treatment. Journal of Antimicrobial Chemotherapy, 42(3), 393–395.
• Sanchez, L., Bacle, A., Lamy, T., & Le-Corre, P. (2019) Potential drugdrug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay. Cancer Chemotherapy and Pharmacology, 83(5), 827– 835. https://doi.org/10.1007/s00280-019-03791-9.
• Tavousi, F., Sadeghi, A., Darakhshandeh, A., & Moghaddas, A. (2019). Potential drug-drug interactions at a referral pediatric oncology ward in Iran: A cross-sectional study. Journal of Pediatric Hematology Oncology, 41(3), e146–e151. https://doi.org/10.1097/ MPH.0000000000001346
• Trevisan, D. D., Silva, J. B., Oliveira, H. C., Secoli, S. R., & Lima, M. H. (2015). Prevalence and clinical significance of potential drugdrug interaction in hematopoietic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 75(2), 393–400. https://doi. org/10.1007/s00280-014-2657-8
• Valenzuela, R., Torres, J. P., Salas, C., Gajardo, I., Palma, J., Catalan, P. … Morales, J. (2017). Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014). Revista Chilena de Infectologia, 34(1), 14–18. https://doi.org/ 10.4067/s0716-10182017000100002
• Zeighami, S., Hadjibabaie, M., Ashouri, A., Sarayani, A., Khoee, S. H., Mousavi, S. … Ghavamzadeh, A. (2014). Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation. Iranian Journal of Pharmaceutical Research, 13(1), 305–312.

Details

Primary Language

English

Subjects

Pharmacology and Pharmaceutical Sciences, Health Care Administration

Journal Section

Research Article

Authors

Nesligül Özdemir ^* This is me
0000-0003-2551-9549
Türkiye

Ayçe Çeliker This is me
0000-0001-6753-6844
Türkiye

Bülent Barış Kuşkonmaz This is me
0000-0002-1207-4205
Türkiye

Duygu Uçkan Çetinkaya This is me
0000-0003-3593-6493
Türkiye

Publication Date

April 30, 2021

Submission Date

April 30, 2020

Acceptance Date

September 29, 2020

Published in Issue

Year 2021 Volume: 51 Number: 1

IZ

https://izlik.org/JA52KD84LZ

Cite

RIS / Bibtex

APA

Özdemir, N., Çeliker, A., Kuşkonmaz, B. B., & Uçkan Çetinkaya, D. (2021). Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. İstanbul Journal of Pharmacy, 51(1), 1-7. https://izlik.org/JA52KD84LZ

AMA

1.Özdemir N, Çeliker A, Kuşkonmaz BB, Uçkan Çetinkaya D. Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. iujp. 2021;51(1):1-7. https://izlik.org/JA52KD84LZ

Chicago

Özdemir, Nesligül, Ayçe Çeliker, Bülent Barış Kuşkonmaz, and Duygu Uçkan Çetinkaya. 2021. “Evaluation of Drug-Drug Interactions and Their Clinical Importance in a Pediatric Hematopoietic Stem Cell Transplantation Unit”. İstanbul Journal of Pharmacy 51 (1): 1-7. https://izlik.org/JA52KD84LZ.

EndNote

Özdemir N, Çeliker A, Kuşkonmaz BB, Uçkan Çetinkaya D (April 1, 2021) Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. İstanbul Journal of Pharmacy 51 1 1–7.

IEEE

[1]N. Özdemir, A. Çeliker, B. B. Kuşkonmaz, and D. Uçkan Çetinkaya, “Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit”, iujp, vol. 51, no. 1, pp. 1–7, Apr. 2021, [Online]. Available: https://izlik.org/JA52KD84LZ

ISNAD

Özdemir, Nesligül - Çeliker, Ayçe - Kuşkonmaz, Bülent Barış - Uçkan Çetinkaya, Duygu. “Evaluation of Drug-Drug Interactions and Their Clinical Importance in a Pediatric Hematopoietic Stem Cell Transplantation Unit”. İstanbul Journal of Pharmacy 51/1 (April 1, 2021): 1-7. https://izlik.org/JA52KD84LZ.

JAMA

1.Özdemir N, Çeliker A, Kuşkonmaz BB, Uçkan Çetinkaya D. Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. iujp. 2021;51:1–7.

MLA

Özdemir, Nesligül, et al. “Evaluation of Drug-Drug Interactions and Their Clinical Importance in a Pediatric Hematopoietic Stem Cell Transplantation Unit”. İstanbul Journal of Pharmacy, vol. 51, no. 1, Apr. 2021, pp. 1-7, https://izlik.org/JA52KD84LZ.

Vancouver

1.Nesligül Özdemir, Ayçe Çeliker, Bülent Barış Kuşkonmaz, Duygu Uçkan Çetinkaya. Evaluation of drug-drug interactions and their clinical importance in a pediatric hematopoietic stem cell transplantation unit. iujp [Internet]. 2021 Apr. 1;51(1):1-7. Available from: https://izlik.org/JA52KD84LZ